Probiotic Lactobacillus strains: in vitro and in vivo studies
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Anti-Bacterial Agents pharmacology MeSH
- Antibiosis MeSH
- Bacterial Translocation MeSH
- Stress, Physiological MeSH
- Interferon-gamma metabolism MeSH
- Interleukin-5 metabolism MeSH
- Liver microbiology MeSH
- Blood microbiology MeSH
- Cells, Cultured MeSH
- Acids pharmacology MeSH
- Lactobacillus drug effects physiology MeSH
- Leukocytes, Mononuclear immunology MeSH
- Mice, Inbred BALB C MeSH
- Mice MeSH
- Probiotics administration & dosage pharmacology MeSH
- Spleen immunology microbiology MeSH
- Tumor Necrosis Factor-alpha metabolism MeSH
- Bile Acids and Salts pharmacology MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Anti-Bacterial Agents MeSH
- Interferon-gamma MeSH
- Interleukin-5 MeSH
- Acids MeSH
- Tumor Necrosis Factor-alpha MeSH
- Bile Acids and Salts MeSH
Three Lactobacillus strains (LOCK 0900, LOCK 0908, LOCK 0919) out of twenty-four isolates were selected according to their antagonistic activity against pathogenic bacteria, resistance to low pH and milieu of bile salts. Intragastric administration of a mixture of these strains to Balb/c mice affected cytokine T(H)1-T(H)2 balance toward nonallergic T(H)1 response. Spleen cells, isolated from lactobacilli-treated mice and re-stimulated in vitro with the mixture of heat-inactivated tested strains, produced significantly higher amounts of anti-allergic tumor necrosis factor- and interferon-gamma than control animals whereas the level of pro-allergic interleukin-5 was significantly lower. Lactobacillus cells did not translocate through the intestinal barrier into blood, liver and spleen; a few Lactobacillus cells found in mesenteric lymph nodes could create antigenic reservoir activating the immune system. The mixture of Lactobacillus LOCK 0900, LOCK 0908 and LOCK 0919 strains represents a probiotic bacterial preparation with possible use in prophylaxis and/or therapy of allergic diseases.
See more in PubMed
Am J Clin Nutr. 2001 Feb;73(2 Suppl):361S-364S PubMed
Lancet. 2001 Apr 7;357(9262):1076-9 PubMed
Folia Microbiol (Praha). 2009;54(2):157-60 PubMed
J Allergy Clin Immunol. 2004 Jul;114(1):131-6 PubMed
Folia Microbiol (Praha). 2008;53(1):61-6 PubMed
Immunol Rev. 2006 Aug;212:238-55 PubMed
Curr Issues Intest Microbiol. 2006 Sep;7(2):73-89 PubMed
Nat Rev Immunol. 2003 Apr;3(4):331-41 PubMed
Int Arch Allergy Immunol. 2003 Jul;131(3):209-11 PubMed
Syst Appl Microbiol. 1998 Dec;21(4):530-8 PubMed
Science. 2004 Mar 12;303(5664):1662-5 PubMed
Folia Microbiol (Praha). 2003;48(2):281-7 PubMed
Appl Environ Microbiol. 1991 May;57(5):1313-8 PubMed
Gene. 2000 Dec 23;259(1-2):245-52 PubMed
J Allergy Clin Immunol. 2001 Jan;107(1):129-34 PubMed
Folia Microbiol (Praha). 2006;51(5):478-84 PubMed
Folia Microbiol (Praha). 2007;52(2):189-93 PubMed
Curr Opin Gastroenterol. 2004 Mar;20(2):146-55 PubMed
Clin Exp Allergy. 2000 Nov;30(11):1604-10 PubMed
